Drug Trial Radar · NCT04732065
ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors
Last checked: Nov 19, 2026Latest source record: Jun 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
208
Planned (sponsor's estimate)
Start
Aug 23, 2021
Primary completion
May 31, 2027
Study completion Jul 31, 2027
Sponsor
- Lead sponsor
- Sabine Mueller, MD, PhDAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Jazz Pharmaceuticals; Mithil Prasad Foundation; Storm the Heavens Fund; The ChadTough Defeat DIPG Foundation; National Cancer Institute (NCI); Dana-Farber Cancer Institute
- First posted
- Feb 1, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 2 years, up to 21 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase I trial studies the effects and best dose of ONC206 alone or in combination with radiation therapy in treating patients with diffuse midline gliomas that is newly diagnosed or has come back (recurrent) or other recurrent primary malignant CNS tumors. ONC206 is a recently discovered compound that may stop cancer cells from growing. This drug has been shown in laboratory experiments to kill brain tumor cells by causing a so called "stress response" in tumor cells. This stress response causes cancer cells to die, but without affecting normal cells. ONC206 alone or in combination with radiation therapy may be effective in treating newly diagnosed or recurrent diffuse midline gliomas and other recurrent primary malignant CNS tumors.
Conditions
- Diffuse Midline Glioma (DMG)
- Glioblastoma
- Recurrent Ependymoma
- Recurrent Malignant Central Nervous System Neoplasm
- Spinal Cord Glioma
- World Health Organization (WHO) Grade III Glioma
- CNS Tumor
- Central Nervous System Tumor
Interventions
ONC206Drug
Given orally (PO)
Standard of Care Radiation TherapyRadiation
Undergo RT
Optional Proton (1H) MR spectroscopy (MRS)Procedure
Optional imaging procedure
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of participants with dose-limiting toxicities (DLT)Time frame: Within 4 weeks after first dose
- Maximum tolerated dose (MTD) of ONC206Time frame: Within 4 weeks after first dose
Locations
7 sites in 3 countries. Site status is shown where the registry gives one.
University of California, San Francisco
San Francisco, California · Recruiting
Children's National Hospital
Washington D.C., District of Columbia · Recruiting
Emory University
Atlanta, Georgia · Recruiting
University of Michigan
Ann Arbor, Michigan · Recruiting
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania · Recruiting
Princess Máxima Center for Pediatric Oncology
Utrecht, Netherlands · Recruiting
The University Children's Hospital in Zurich
Zurich, Canton of Zurich, Switzerland · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.